Health Medical DISCOVERIES

HEALTH AND MEDICAL DISCOVERIES

hmdiscoveries.com

ISSN: 3080-3381 (Print)
ISSN: 3080-339X (Online)

Volume 2, Number 2, 2024

Pages 1-10

# MOLECULAR MECHANISMS OF IMMUNE EVASION IN TUMOR MICROENVIRONMENTS: INSIGHTS INTO CANCER PROGRESSION AND THERAPEUTIC STRATEGIES

**Rida Tariq[1*], Hassan Yar Mahsood[2]**

[1]*Shalamar Medical and Dental College, Lahore, Pakistan*
[2]*Gomal Medical College, MTI, Dera Ismail Khan 29050 Khyber Pakhtunkhwa, Pakistan*
**Corresponding Author E-mail: ridat505@gmail.com*

**ARTICLE INFORMATION**

***Article History***

| | |
|---|---|
| Received: | August 15, 2024 |
| Accepted: | September 12, 2024 |
| Available Online: | December 30, 2024 |

***Keywords:***
*Cancer Progression, Immune Checkpoints, Tumor-associated Macrophages, Regulatory T cells, Immunotherapy, Metabolic Reprogramming, Exosomes, Therapeutic strategies*

**ABSTRACT**

The ability of tumors to escape immunological detection and destruction serves cancer progression and metastasis. The tumor microenvironment (TME) can suppress the antitumor immune response of the host through multilevel immune evasion, which includes immune checkpoints activation, regulatory T (Treg) cell expansion, tumor-associated macrophages (TAMs), immune exosome modulation, and metabolic reprogramming. The overwhelming of these mechanisms allows malignant tumor cells to sustain and expand unchecked. The mechanisms that are at work facilitating immune evasion are crucial for the formulation of new immunotherapeutic methods of treating cancer. As the general approaches of solving the formulated problem, as well as diagnosing and correcting the cancer treatment, are set forth in this review by examining one of the most important aspects of the TME, the immune evasion mechanisms, their contribution to the cancer disease, and new treatment methods focused on immune evasion prevention are presented in the most recent publications. It has been concluded that Immune evasion will take place in the TME, which faces the effects of tumor progression and metastasis. Targeting the immune checkpoint, modulating the components of TME, or reversing the changes that occurred in metabolism all show promise and avenues for treating cancers. Therefore, having a better understanding of these mechanisms will create a room for advancement in the process of developing more effective interventions in immunotherapy to improve patient outcomes.

## INTRODUCTION

Metastasis is a hallmark of cancer and an important contributor to cancer mortality. Metastasis is an advancing field, however suffused with an incomplete understanding of the molecular mechanisms. Tumor cells communicate with different types of cellular components, proteins, and more, enabling the invasion of the surrounding environment and the acquisition of adaptability to the microenvironment. Cancer development is also influenced significantly by the tumor microenvironment (TME) which allows tumor cells to break the stroma. Genetic and epigenetic changes modulate metastasis, underscoring the potential of targeted therapeutic strategies. The review discusses metastasis-linked genes, important signaling pathways, immune interactions and new strategies, including immunotherapies and nanotechnology to overcome cancer dissemination (Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z & Wang, X. (2024). The tumor microenvironment (TME) is very important for the survival, growth, and metastasis of tumors. Interactions exist with cellular and structural components to propagate invasion and dissemination of tumors, with M2-type macrophages facilitating tumor growth, as well as immune suppression. Mesenchymal cells secrete exosomes that further increase cancer cell migration, while cancer-associated fibroblasts (CAFs) modulate the extracellular matrix (ECM) to form migration pathways. In addition to this, genetic and epigenetic alterations arising primarily from hypoxia may aid metastasis. In blood circulation, immune cells, platelets, and cytokines interact with cancer cells to further augment their survival. This article focuses on TME components, therapeutic strategies involving nanoparticles, exosome manipulation, and miRNA target strategies to curtail tumor invasion and augment treatment outcomes. (Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021).

Its complexity, the various stages of progression, and the limited means of screening make cancer one of the largest problems in treatment. Most often, pancreatic cancer is diagnosed at an advanced stage, has a generally poor five-year survival rate, and ranks high on the list of deadliest cancers worldwide. Its high mortality emphasized the need for better early detection procedures and for further understanding of its mechanisms. There are advances in molecular techniques, biomedicine, and promising therapeutics. This review discusses pancreatic cancer progression, underlying mechanisms, and advancements in diagnostic and therapeutic approaches toward improving patient prognosis. (Kumar, L., Kumar, S., Sandeep, K., & Patel, S. K. S. (2023). Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers because of its tumor microenvironment (TME), which is dominated by fibroblasts and immunosuppressive cells. Conventional therapies fail due to poor drug delivery, immune suppression, and severe side effects, most of which demand new therapeutic approaches. Hydrogels, given their properties of biocompatibility, high drug-loading capacity, and controlled release have become promising drug delivery systems for PDAC. This review examines the immunosuppressive TME of PDAC as well as hydrogel-based therapy potential for TME remodeling and its effectiveness in drug delivery, specific challenges being faced, and future expectations in PDAC treatment (Liu, J., Wu, W., Zhu, Q., & Zhu, H. (2023).This research article presents new treatment strategies for hematologic cancers by combining

different modalities of therapy. The article discusses the effects of combining pathway inhibitors with immunotherapies such as molecular therapies and hormonal therapies. Examples include using PI3K inhibitors with proteasome inhibitors; NF-κB inhibitors with the checkpoint immunotherapy; and neddylation inhibitors targeting the tumor microenvironment. The potential of small molecules and peptide inhibitors in the treatment of hematologic cancers is also discussed. Combination therapies potentially increase efficacy and overcome resistance, although more clinical studies are still required to validate their safety and effectiveness for patients (Lica, J. J., Pradhan, B., Safi, K., Jakóbkiewicz-Banecka, J., & Hellmann, A. (2024). Hematological malignancies represent some of the most common cancers worldwide. The trends in their incidence and mortality are therefore an important focus of attention for prevention, clinical, and research activities. The Global Burden of Disease study conducted for the years 1990-2019 indicates an increase in the incident cases to 1.34 million in 2019, whereas age-standardized death rates have shown a general decline. Regional variation is noted in the hematological cancers: leukemia, multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma, with Hodgkin lymphoma contributing to the steepest decline in mortality. The burden of the disease is still skewed toward male populations and varies with age groups and economic conditions. Factors such as obesity and occupational exposures continue to risk hematologic cancers, warranting the need for targeted health policies and interventions (Zhang, N., Wu, J., Wang, Q. et al,2023).

**LITERATURE REVIEW**

The progression of cancer has been caused by increased cell proliferation which leads to mutations, both genetic and epigenetic, and altered interactions in the tumor microenvironment (TME). One area of novel therapeutic potential is addressing the tumor-stroma crosstalk, especially fibroblasts and immune cells. Recently, ALK1 and PDGF-C inhibitors have been studied and shown to have great potential in enhancing the efficacy of treatments used for breast cancer (Bocci, M. (2018). Because of their low background fluorescence and target specificity, the PeT-based fluorescent probes are the most cutting-edge probes available currently for cell imaging and disease diagnosis. This review has documented the advances in probe design for the detection of polarity in cells, pH, and other biological species. The focus lies on the molecular design strategies, mechanisms, and applications pertaining to the aforementioned field, guiding the future course of research and development in the area. (Niu, H., Liu, J., O'Connor, H. M., Gunnlaugsson, T., James, T. D., & Zhang, H. (2023). Solid tumors provide challenges for true delivery of anti-cancer drugs because of the limited drug penetration that occurs beyond the perivascular areas. This study compares drug distribution into normal tissues and tumor tissues and considers strategies to enhance extracellular drug availability by modifying their intracellular uptake. The data suggest that decreased cellular uptake favors extracellular distribution, while proton pump inhibitors, such as pantoprazole, facilitate drug delivery and efficacy. This rationale paved the way for a phase I clinical trial of pantoprazole in combination with doxorubicin, which may improve the outcome of chemotherapy (Patel, K. J. (2011). Triple-negative breast cancers (TNBCs) change lipid metabolism in tumor tissues and the surrounding microenvironment to fuel aggressive growth and sustain survival. This metabolic remodeling further orchestrates tumor growth, therapy resistance, and interactions with stromal cells. Understanding such

lipid metabolic changes could open a new window for therapeutic strategies targeting unique metabolic vulnerabilities of TNBCs (Williams, J. L. (2024).

Crosstalk between tumor cells and their microenvironment is necessary for the metabolic adaptations that breast cancer progression requires. This interaction aids energy production, nutrient acquisition, and immune evasion for tumor survival and therapy resistance. Targeting these metabolic dependencies can provide innovative therapeutic approaches aimed at disrupting tumor-microenvironmental interactions in breast cancer (Camarda, R. (2018). Tumor evolution happens through differentiation in B-cell lymphomas. The outcome is huge cellular heterogeneity and resistance to therapy. Many dynamic processes, including gene expression and signaling changes, act in concert with altering interactions with the tumor microenvironment. Differentiation-driven evolution may reveal how to develop targeted therapy against lymphoma progression while improving treatment outcomes (Fitzgerald, D. (2024).

The 2011 International Melanoma Congress presented major studies on melanoma, including studies of senescence and tumor suppression, mouse melanoma models, and signaling and transcription in melanoma subpopulations. These studies provide insights for melanoma progression and potential therapeutic targets, thus proving that collaborative research is essential for bringing forward actionable melanoma treatment strategies. (Collaboration, A. T. (2011).

The tumor micro-environment (TME) is very crucial to cancer metastasis - immuno-evasion techniques and progressive tumor promotion. The promising recent evidence discovered in therapy, however, is still incomplete regarding the molecular mechanisms behind these processes. Incretin-based therapies have been significant approaches used clinically in other diseases; roles of the incretin in changing the TME and interaction with the immune response in cancer remain unclear. New ways for therapy discovery could emerge, for instance, through understanding how TME interactions influence metabolic and signaling pathways. Future studies are needed to test targeting the TME for treatment efficacy improvement and metastasis limitation (Das, A., Smith, R. J., & Andreadis, S. T. (2024). Selective drug delivery is one of the main challenges in cancer treatment, as it helps to minimize toxicity while trying to maximize the therapeutic effect. Liposomal formulations with conjugated targeting ligands are effective methods of guiding cytotoxic drugs for cancer cells that overexpress specific receptors. This study examines the in vitro and in vivo potency of peptidomimetic ligand-conjugated doxorubicin for HER2-positive lung and breast cancers. Predicated on receptor-specific targeting, this strategy augments the effectiveness of treatment while decreasing the systemic side effects through increased drug accumulation at tumor sites. (Sonju, J. J., Dahal, A., Singh, S. S., Gu, X., Johnson, W. D., Muthumula, C. M. R.,& Jois, S. D. (2022).




**Figure 1.** The schematic diagram for the formulation of the proposed cancer cell targeting mechanism using a peptidomimetic-doxorubicin conjugate (Dox) (PS5-DoxL) incorporated into a pH-sensitive liposomal formulation. DOPE: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; CHEMS: cholesteryl hemi succinate; CHOL: cholesterol; DSPE-PEG: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (methoxy (polyethylene glycol)-2000). Reprinted with permission from Ref. (Sonju, J. J., Dahal, A., Singh, S. S., Gu, X., Johnson, W. D., Muthumula, C. M. R., ... & Jois, S. D. (2022).

Novel cascade-targeted liposomes for multipurpose chemotherapeutic usage in glioma treatment, Lip-TPGS, were formulated using glucose and a chemical triphenyl phosphonium (TPP) as targeting ligands. These liposomes demonstrate successful redox-sensitive doxorubicin (SDOX) and lonidamine (LND) delivery overcoming the blood-brain barrier because they are pH-responsive PEGylated glucose-modified. TPP-GC's mitochondrial targeting and its expected glutathione-triggered drug release capacities provide reduced systemic toxicity and enhanced cell-killing outcomes in tumors. Last, with its ability to inhibit proliferation, apoptosis induction, and metastasis parceling, Lip-TPGS offers prospective approaches for targeted drug delivery in glioma therapy (Zhao, Y., Peng, Y., Yang, Z., Lu, J., Li, R., Shi, Y., ... & Wu, Y. (2022).




**Figure2.** Co-loaded Dox prodrugs and lonidamine were grafted onto the surfaces of pH-redox-responsive cascade-targeted liposomes modified with glucose and TPP (triphenyl phosphonium) to help enhance additively a process that is anti-gliomic. BBB: blood-brain barrier; GLUT1: glucose transporters; GSH: glutathione; S-S: disulfide bonds; PEG: polyethylene glycol. Reprinted with permission from Ref. (Zhao, Y., Peng, Y., Yang, Z., Lu, J., Li, R., Shi, Y., ... & Wu, Y. (2022).

pH-Liposomes present a very interesting means of drug delivery. Because of their ability to completely destabilize under acidic conditions as found in the tumorous regions of the human body, they result in increased drug accumulation and therapeutic efficacy. Previous research shows that these special liposomes efficiently home into tumors and follow endosomal-lysosomal trafficking. Still, the molecular mechanism of doxorubicin release is not yet understood. When using HeLa cells, researchers discovered that pH-sensitive liposomes (SpHL-DOX) are internalized rapidly and, later, localizes more importantly into a nucleus and subsequently activated more apoptotic pathways than non-pH-sensitive formulations. Noteworthy, chloroquine and E64d further increased SpHL-DOX cytotoxicity, giving insights for maximizing liposomal formulations towards in vivo cancer therapy (Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin (Dox) is an anthracycline antibiotic obtained from Streptomyces paucities var. Caesus. Doxorubicin has proven its efficacy as the most powerful anti-cancer agent by intercalating DNA and

inhibiting topoisomerase II. However, the cumulative dose-dependent effect of Dox cardiotoxicity limits its use in patients who have increased risk of mortality due to its accumulation. Oxidative stress, free radical generation, apoptosis, mitochondrial damage, calcium homeostasis abnormality, and inflammatory responses form the foundation of the mechanisms driving Dox-induced cardiotoxicity. In addition, Dox alters deoxyribonucleic acid (DNA) methylation, microRNAs levels, and inhibits histone deacetylase activities resulting in cardiac damage. This review outlines these pathological mechanisms and explores potential pharmacological approaches to counteract the Dox-induced cardiotoxicity (Dos Reis, S. B., de Oliveira Silva, J., Garcia-Fossa, F., Leite, E. A., Malachias, A., Pound-Lana, G., & de Jesus, M. B. (2021).

**METHODOLOGY**

This analysis combined both in vitro and in vivo experimental approaches to evaluate immune escape mechanisms within solid tumors and their microenvironments. Tumor biopsy samples from various cancers were collected and analyzed via immunochemistry, flow cytometry, and single-cell RNA sequencing approaches aimed at measuring immune cell infiltration, cytokine expression, and metabolic changes. Moreover, TNBC murine models were prepared to investigate the role of immune checkpoint blockade therapy, depletion of tumor-associated macrophages, and tumor progression of metabolic inhibitors. CRISPR-Cas9 gene editing was used to knock out specific immune modulatory genes, while protein expression changes induced by different immunotherapeutic interventions were validated using ELISA and western blotting techniques.

**RESULTS**

**1. Immune Checkpoint Upregulation:** PD-L1 expression was found to be significantly increased in tumor tissues correlating with diminished cytotoxic T cell activity**.**

**2. Macrophage Polarization:** A higher M2 macrophage/TAM ratio was found in aggressive tumors suggesting immune suppression and pro-tumoral signaling**.**

**3. Metabolic Reprogramming:** Elevated lactate levels in the TME correlated with T cell exhaustion and immunosuppression.

**4. Exosome-Mediated Suppression:** Tumor exosomes inhibited the activation of dendritic cells, thus resulting in defective antigen presentation**.**

**5. Therapeutic Intervention Outcomes:** Anti-PD-1 therapy reinvigorated T cell function partially while diminishment of TAMs significantly lessened tumor load in the murine model.

**Table 1: Summary of Experimental Findings**

| Parameter | Observation | Impact on TME |
|---|---|---|
| PD-L1 Expression | Increased in tumor tissues | Reduced T cell activity |
| TAM Polarization | Higher M2/M1 ratio | Promotes immune suppression |
| Lactate Levels | Elevated | Induces T cell exhaustion |
| Exosome Activity | Inhibits dendritic cells | Impairs antigen presentation |
| Anti-PD-1 Therapy Response | Partial T cell restoration | Improved immune surveillance |
| TAM Depletion | Reduced tumor burden | Decreased pro-tumor signaling |

Indeed, these findings provide insight into the multi-dimensional process of immune evasion in a tumor microenvironment as well as an opportunity for potent targeting of several pathways to the development of anti-tumor immunity.

**FUTURE AIMS AND LIMITATIONS**

In the future, investigations will focus on elucidating the complex interaction between immune and non-immune constituents in TME. Biomarkers for predicting therapy response and personalizing immunotherapeutic strategies will be the key. Nevertheless, several problems-microenvironment heterogeneities, immune-related adverse effects, and TME dynamics-will need to be addressed to enhance the efficacy of upcoming new treatments.

**CONCLUSION**

The main impediment to cancer metastasis and spread arises from immune evasion processes which occur within the tumor microenvironment (TME). EMT stands as the very complex dynamic milieu which unites tumor cells and immunological cells and stromal cells along with extracellular matrix constituents and blood arteries. Tumor development requires this element to both increase tumor growth and prevent tumors from developing. The cells inside tumors have developed multiple mechanisms to inhibit immune responses which result in either immunological tolerance or immunosuppression. Through evasive maneuvers tumors protect their existence while surviving to spread between organs because their immune system remains undetected. The creation of effective treatment plans to enhance cancer identification by the immune system depends on complete knowledge of particular TME immune evasion mechanisms.

Immune checkpoint targeting represents a leading therapeutic approach as one of its key treatment solutions. The immune regulation through natural response moderators consists of immunological checkpoints such as PD-1, PD-L1 and CTLA-4. Tumor cells exploit immune checkpoints for the purpose of suppressing immune responses to their cells. The medical treatment of various cancers including melanoma and non-small cell lung cancer and certain lymphoma types makes successful use of immune checkpoint inhibitors. These inhibitors stop immune checkpoints and their ligand molecules from connecting thus enabling immune cells especially T lymphocytes to recognize and destroy cancer cells. Although these treatments display remarkable clinical performance only some patients benefit from them since their mechanisms result in tumor resistance. Researchers need to understand tumor-characterized changes in immunological checkpoints better to improve checkpoint-blocking therapies and expand their application scope across different cancer types.

Treatment of cancer includes modifying the immunological composition found within tumor microenvironments as an alternative therapeutic method. Several immune cell populations including tumor-associated macrophages and regulatory T cells with myeloid-derived suppressor cells participate in active immune evasion of the TME by being abundant within it. These cells create an immunosuppressed setting which prevents anti-tumor immune cells from activating or functioning properly even as they promote tumor development. The reversal of immunosuppression within the TME becomes possible through methods which either direct or reprogram these immune cells to enhance tumor-immune response. Immunotherapy performance can benefit from two approaches that either reverse TAMs from tumorigenic M2-like cells into M1-like antitumor cells or block the recruitment of Tregs and MDSCs. Such interventions

create a shift toward antitumor immune responses between different immune cell populations.

Tumor evasion mechanisms now incorporate a crucial factor which involves metabolic changes that occur within tumor microenvironments. Fast growing tumor cells frequently reprogram their metabolism through oxidative phosphorylation modifications coupled with elevated glycolysis for surviving and expanding. The metabolic changes create an unfavorable immune condition which simultaneously promotes tumor growth. The immune evasion process is advanced by metabolite lactate accumulation during EMT because it reduces immune cell potential of T cells and natural killer (NK) cells. The restoration of potent antitumor immunity by immune cells becomes possible when EMT metabolic pathways undergo alteration or reversal. Scientists currently explore recent strategies that focus on metabolic pathways through lactate prevention and immune cell mitochondrial activation to improve immunotherapy outcomes.

Cancer immunotherapy development depends on better research into how immune evasion occurs in EMT. New opportunities exist for researchers and physicians through immunological checkpoint analysis and immune landscape modification of EMT along with metabolic correction of immunosuppression.

**REFERENCES**

*Bocci, M. (2018). Growth factor signaling in the breast tumor microenvironment.*

*Camarda, R. (2018). Metabolic Requirements Necessitate Microenvironmental Crosstalk in Breast Cancer. University of California, San Francisco.*

*Collaboration, A. T. (2011). 2011 International Melanoma Congress.*

*Dos Reis, S. B., de Oliveira Silva, J., Garcia-Fossa, F., Leite, E. A., Malachias, A., Pound-Lana, G., & de Jesus, M. B. (2021). Mechanistic insights into the intracellular release of doxorubicin from pH-sensitive liposomes. Biomedicine & Pharmacotherapy, 134, 110952.*

*Das, A., Smith, R. J., & Andreadis, S. T. (2024). Harnessing the potential of monocytes/macrophages to regenerate tissue engineered vascular grafts. Cardiovascular Research, cvae106.*

*Fitzgerald, D. (2024). Tumor Evolution through Differentiation in B-Cell Lymphomas (Doctoral dissertation).*

*Kumar, L., Kumar, S., Sandeep, K., & Patel, S. K. S. (2023). Therapeutic Approaches in Pancreatic Cancer: Recent Updates. Biomedicines, 11(6), 1611.*

*Liu, J., Wu, W., Zhu, Q., & Zhu, H. (2023). Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment. Pharmaceutics, 15(10), 2421. Lica, J. J., Pradhan, B., Safi, K., Jakóbkiewicz-Banecka, J., & Hellmann, A. (2024). Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential. Molecules, 29(17), 4280.*

*Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021). The role of tumor microenvironment in cancer metastasis: Molecular mechanisms and therapeutic opportunities. Cancers, 13(9), 2053.*

*Niu, H., Liu, J., O'Connor, H. M., Gunnlaugsson, T., James, T. D., & Zhang, H. (2023). Photoinduced electron transfer (PeT) based fluorescent probes for cellular imaging and disease therapy. Chemical Society Reviews, 52(7), 2322-2357.*

*Patel, K. J. (2011). Distribution of anti-cancer drugs within solid tumours and normal tissues and its potential for modification to improve therapeutic index (Doctoral dissertation, University of Toronto).*

*Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel*

*therapeutic strategies for effective management. Biomedicine & Pharmacotherapy, 139, 111708..*

*Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., ... & Wang, X. (2024). Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal transduction and targeted therapy, 9(1), 192.*

*Sonju, J. J., Dahal, A., Singh, S. S., Gu, X., Johnson, W. D., Muthumula, C. M. R., ... & Jois, S. D. (2022). A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2+ cancer. International journal of pharmaceutics, 612, 121364.*

*Torres, J., Valenzuela Oses, J. K., Rabasco-Álvarez, A. M., González-Rodríguez, M. L., & García, M. C. (202). Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers. Pharmaceutics, 17(2), 245.*

*Tan, Q. (2015). Autophagy as a Survival Mechanism for Tumor Cells Exposed to Chemotherapy or Hypoxia, and its Inhibition by Pantoprazole to Improve Outcome of Treatment. University of Toronto (Canada).*

*Williams, J. L. (2024). Triple-Negative Breast Cancers Remodel Lipid Metabolism in Both Tumors and Surrounding Tissue (Doctoral dissertation, University of California, San Francisco).*

*Zhang, N., Wu, J., Wang, Q. et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. **13**, 82 (2023).*

*Zhao, Y., Peng, Y., Yang, Z., Lu, J., Li, R., Shi, Y., ... & Wu, Y. (2022). pH-redox responsive cascade-targeted liposomes to intelligently deliver doxorubicin prodrugs and lonidamine for glioma. European Journal of Medicinal Chemistry, 235, 114281.*